Jeil Pharmaceutical Co.,Ltd (271980.KS)
KRW 11640.0
(-5.6%)
KRW 11640.0
(-5.6%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 8.73 Billion KRW | 166.67% |
| 2022 | -13.33 Billion KRW | -136.57% |
| 2021 | -5.63 Billion KRW | -143.67% |
| 2020 | 12.9 Billion KRW | 1118.56% |
| 2019 | 1.05 Billion KRW | -85.67% |
| 2018 | 7.39 Billion KRW | 48.81% |
| 2017 | 4.96 Billion KRW | -46.9% |
| 2016 | 9.35 Billion KRW | -28.86% |
| 2015 | 13.14 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -15.14 Billion KRW | -565.86% |
| 2024 Q1 | -2.27 Billion KRW | -54.5% |
| 2023 FY | 8.88 Billion KRW | 166.67% |
| 2023 Q3 | -2.65 Billion KRW | 17.49% |
| 2023 Q2 | -3.21 Billion KRW | -119.88% |
| 2023 Q1 | 16.17 Billion KRW | 424.79% |
| 2023 Q4 | -1.47 Billion KRW | 44.49% |
| 2022 Q4 | -4.97 Billion KRW | -79.14% |
| 2022 Q1 | -3.47 Billion KRW | 44.51% |
| 2022 Q2 | -2.19 Billion KRW | 36.93% |
| 2022 FY | -13.33 Billion KRW | -136.57% |
| 2022 Q3 | -2.77 Billion KRW | -26.76% |
| 2021 Q4 | -6.26 Billion KRW | -148.67% |
| 2021 Q2 | -955.16 Million KRW | -20.68% |
| 2021 Q1 | -791.5 Million KRW | -139.5% |
| 2021 FY | -5.63 Billion KRW | -143.67% |
| 2021 Q3 | -2.51 Billion KRW | -163.73% |
| 2020 Q3 | 1.18 Billion KRW | -73.24% |
| 2020 Q1 | 5.26 Billion KRW | 160.0% |
| 2020 FY | 12.9 Billion KRW | 1118.56% |
| 2020 Q4 | 2 Billion KRW | 68.52% |
| 2020 Q2 | 4.44 Billion KRW | -15.66% |
| 2019 FY | 1.05 Billion KRW | -85.67% |
| 2019 Q3 | 2.56 Billion KRW | -43.07% |
| 2019 Q2 | 4.5 Billion KRW | 116.68% |
| 2019 Q1 | 2.08 Billion KRW | -49.91% |
| 2019 Q4 | -8.77 Billion KRW | -442.08% |
| 2018 Q1 | 729.63 Million KRW | -70.96% |
| 2018 FY | 7.39 Billion KRW | 48.81% |
| 2018 Q4 | 4.15 Billion KRW | 133.3% |
| 2018 Q3 | 1.78 Billion KRW | 144.86% |
| 2018 Q2 | 727.04 Million KRW | -0.36% |
| 2017 Q2 | 392.02 Million KRW | 0.0% |
| 2017 Q4 | 2.51 Billion KRW | 21.92% |
| 2017 FY | 4.96 Billion KRW | -46.9% |
| 2017 Q3 | 2.06 Billion KRW | 425.77% |
| 2016 FY | 9.35 Billion KRW | -28.86% |
| 2015 FY | 13.14 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -2295.196% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 88.643% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 110.974% |
| HANDOK Inc. | 12.57 Billion KRW | 30.587% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 538.952% |
| Yuhan Corporation | 74.56 Billion KRW | 88.29% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 21.891% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 148.393% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 96.117% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -185.707% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 39.156% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -1364.007% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -805.965% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 67.699% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -2295.196% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 212.575% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -116.465% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 112.482% |
| JW Holdings Corporation | 143.66 Billion KRW | 93.922% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 116.346% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 96.459% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 91.295% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 118.424% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -26.05% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -34.93% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -2295.196% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 82.096% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 93.455% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 91.295% |
| Yuhan Corporation | 74.56 Billion KRW | 88.29% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 58.263% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -180.086% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 79.692% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 91.295% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 57.375% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 84.11% |
| CKD Bio Corp. | -20.15 Billion KRW | 143.326% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 72.912% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 65.491% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 73.155% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 118.424% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 73.659% |
| Boryung Corporation | 68.26 Billion KRW | 87.21% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 123.286% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 39.156% |
| JW Lifescience Corporation | 32.09 Billion KRW | 72.792% |